<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01583166</url>
  </required_header>
  <id_info>
    <org_study_id>14197</org_study_id>
    <nct_id>NCT01583166</nct_id>
  </id_info>
  <brief_title>Voiding Function After Mid-Urethral Slings With and Without Local Anesthetic: Randomized Controlled Trial</brief_title>
  <acronym>URINE&amp;ME</acronym>
  <official_title>Voiding Function After Mid-Urethral Slings With and Without Local Anesthetic: Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if there is a difference in post-operative voiding
      function between subjects receiving local anesthetic and those receiving placebo at the time
      of mid-urethral sling placement. The secondary objective is to evaluate pain after the
      procedure in the two groups.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Who Passed the Voiding Trial After a Midurethral Sling</measure>
    <time_frame>2 weeks</time_frame>
    <description>Study team assessment of whether the use of local anesthetic has any affect on the percentage of patients who pass their post-operative bladder challenge. This is determined by their voided volume and post-void residual.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-operative Pain Scores at 2-3 Hours Post op</measure>
    <time_frame>2-3 hours</time_frame>
    <description>Visual analog score at 2 hours post op will be compared in the two groups. The scale ranges from 0 (no pain) to a maximum of 10 (unbearable pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative Pain Scale at 6-7 Hours Post op</measure>
    <time_frame>6-7 hours</time_frame>
    <description>Visual analog score at 6 hours post op will be compared in the two groups. The scale ranges from 0 (no pain) to a maximum of 10 (unbearable pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale for Pain: Pre-operative.</measure>
    <time_frame>At enrollment</time_frame>
    <description>Participants asked to report on pre-operative level of pain using a Visual Analog Scale. The scale is participant reported and ranges from 0 representing no pain to 10 representing unbearable pain.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Stress Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Bupivacaine + epinephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline + epinephrine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>10ml 0.5% bupivacaine</description>
    <arm_group_label>Bupivacaine + epinephrine</arm_group_label>
    <other_name>Marcaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>10ml 0.9% sodium chloride</description>
    <arm_group_label>Saline + epinephrine</arm_group_label>
    <other_name>Sodium Chloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine</intervention_name>
    <description>1:200,000 epinephrine</description>
    <arm_group_label>Bupivacaine + epinephrine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled to undergo mid-urethral sling for incontinence without concomitant
             procedures

        Exclusion Criteria:

          -  Undergoing procedure in addition to the sling

          -  Not competent to give consent

          -  Using intermittent self catheterization pre-operatively

          -  Known allergy to local anesthetic

          -  Undergoing spinal anesthesia for the procedure

          -  Prisoners

          -  Non-English speaker

          -  Under 18 years of age

          -  Has a condition that would contra-indicate the use of local anesthetic or epinephrine
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Flynn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Massachusetts, Worcester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Massachusetts</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>April 19, 2012</study_first_submitted>
  <study_first_submitted_qc>April 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2012</study_first_posted>
  <results_first_submitted>May 2, 2018</results_first_submitted>
  <results_first_submitted_qc>October 29, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 28, 2018</results_first_posted>
  <last_update_submitted>October 29, 2018</last_update_submitted>
  <last_update_submitted_qc>October 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>Michael Flynn</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects with stress incontinence or stress-predominant mixed urinary incontinence who were scheduled to undergo a retropubic midurethral sling with no concomitant procedures at UMass Memorial Healthcare, Inc.
Enrollment occurred from March 2012 to June 2015 with study presented and consent sought at time of preoperative appointment.</recruitment_details>
      <pre_assignment_details>10 participants did not receive allocated intervention--patient-initiated cancellation of surgery. (Saline + Epinephrine n=6, Bupivavane + Epinephrine n=4). Midway through study, indigo carmine became unavailable and surgical team opted for phenazopyridine. Failed to obtain 6-7 hour pain score in 24 out of 80 subjects.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Marcaine + Epinephrine</title>
          <description>Bupivicaine + epinephrine: 10ml 0.5% bupivicaine plus 1:200,000 epinephrine</description>
        </group>
        <group group_id="P2">
          <title>Saline + Epinephrine</title>
          <description>Sodium chloride + epinephrine: 10ml 0.9% sodium chloride plus 1:200,000 epinephrine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Marcaine + Epinephrine</title>
          <description>Bupivicaine + epinephrine: 10ml 0.5% bupivicaine plus 1:200,000 epinephrine</description>
        </group>
        <group group_id="B2">
          <title>Saline + Epinephrine</title>
          <description>Sodium chloride + epinephrine: 10ml 0.9% sodium chloride plus 1:200,000 epinephrine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="39"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>all subjects were included in the baseline assessments
the final numbers in the results section differ due to subject withdrawal or drop out</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.0" spread="11.6"/>
                    <measurement group_id="B2" value="50.5" spread="11.1"/>
                    <measurement group_id="B3" value="48.1" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <population>45 randomized to each, number analyzed differs due to participant withdrawal</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visual Analog Scale for Pain: Preoperative</title>
          <description>Participants were asked to report on pre-operative level of pain using a Visual Analog Scale, The scale is participant reported and ranged form 0 representing no pain to 10 representing unbearable pain.</description>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.0" spread="1"/>
                    <measurement group_id="B2" value="0.0" spread="1.4"/>
                    <measurement group_id="B3" value="0.0" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Passed the Voiding Trial After a Midurethral Sling</title>
        <description>Study team assessment of whether the use of local anesthetic has any affect on the percentage of patients who pass their post-operative bladder challenge. This is determined by their voided volume and post-void residual.</description>
        <time_frame>2 weeks</time_frame>
        <population>Passed void trial</population>
        <group_list>
          <group group_id="O1">
            <title>Marcaine + Epinephrine</title>
            <description>Bupivicaine + epinephrine: 10ml 0.5% bupivicaine plus 1:200,000 epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Saline + Epinephrine</title>
            <description>Sodium chloride + epinephrine: 10ml 0.9% sodium chloride plus 1:200,000 epinephrine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Passed the Voiding Trial After a Midurethral Sling</title>
          <description>Study team assessment of whether the use of local anesthetic has any affect on the percentage of patients who pass their post-operative bladder challenge. This is determined by their voided volume and post-void residual.</description>
          <population>Passed void trial</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-operative Pain Scores at 2-3 Hours Post op</title>
        <description>Visual analog score at 2 hours post op will be compared in the two groups. The scale ranges from 0 (no pain) to a maximum of 10 (unbearable pain)</description>
        <time_frame>2-3 hours</time_frame>
        <population>Please notice that the number of subjects is different because we only analyzed the pain scores from the subjects who were randomized and had the surgery. We also had some missing pain scores</population>
        <group_list>
          <group group_id="O1">
            <title>Marcaine + Epinephrine</title>
            <description>Bupivicaine + epinephrine: 10ml 0.5% bupivicaine plus 1:200,000 epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Saline + Epinephrine</title>
            <description>Sodium chloride + epinephrine: 10ml 0.9% sodium chloride plus 1:200,000 epinephrine</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Pain Scores at 2-3 Hours Post op</title>
          <description>Visual analog score at 2 hours post op will be compared in the two groups. The scale ranges from 0 (no pain) to a maximum of 10 (unbearable pain)</description>
          <population>Please notice that the number of subjects is different because we only analyzed the pain scores from the subjects who were randomized and had the surgery. We also had some missing pain scores</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="2"/>
                    <measurement group_id="O2" value="2.9" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.837</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-operative Pain Scale at 6-7 Hours Post op</title>
        <description>Visual analog score at 6 hours post op will be compared in the two groups. The scale ranges from 0 (no pain) to a maximum of 10 (unbearable pain)</description>
        <time_frame>6-7 hours</time_frame>
        <population>Study team failed to obtain 6-7 hour pain score for 24 out of the 80 participants. The overall number of participants analyzed reflects this occurence.</population>
        <group_list>
          <group group_id="O1">
            <title>Marcaine + Epinephrine</title>
            <description>Bupivicaine + epinephrine: 10ml 0.5% bupivicaine plus 1:200,000 epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Saline + Epinephrine</title>
            <description>Sodium chloride + epinephrine: 10ml 0.9% sodium chloride plus 1:200,000 epinephrine</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Pain Scale at 6-7 Hours Post op</title>
          <description>Visual analog score at 6 hours post op will be compared in the two groups. The scale ranges from 0 (no pain) to a maximum of 10 (unbearable pain)</description>
          <population>Study team failed to obtain 6-7 hour pain score for 24 out of the 80 participants. The overall number of participants analyzed reflects this occurence.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="1.6"/>
                    <measurement group_id="O2" value="4.1" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale for Pain: Pre-operative.</title>
        <description>Participants asked to report on pre-operative level of pain using a Visual Analog Scale. The scale is participant reported and ranges from 0 representing no pain to 10 representing unbearable pain.</description>
        <time_frame>At enrollment</time_frame>
        <population>Please noticed that there is a discrepancy with the number of subjects. We include the data from all subjects who were randomized and had the intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Marcaine + Epinephrine</title>
            <description>Bupivicaine + epinephrine: 10ml 0.5% bupivicaine plus 1:200,000 epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Saline + Epinephrine</title>
            <description>Sodium chloride + epinephrine: 10ml 0.9% sodium chloride plus 1:200,000 epinephrine</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale for Pain: Pre-operative.</title>
          <description>Participants asked to report on pre-operative level of pain using a Visual Analog Scale. The scale is participant reported and ranges from 0 representing no pain to 10 representing unbearable pain.</description>
          <population>Please noticed that there is a discrepancy with the number of subjects. We include the data from all subjects who were randomized and had the intervention.</population>
          <units>Reported Pain Level score on VAS</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="1"/>
                    <measurement group_id="O2" value="0.0" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Marcaine + Epinephrine</title>
          <description>Bupivicaine + epinephrine: 10ml 0.5% bupivicaine plus 1:200,000 epinephrine</description>
        </group>
        <group group_id="E2">
          <title>Saline + Epinephrine</title>
          <description>Sodium chloride + epinephrine: 10ml 0.9% sodium chloride plus 1:200,000 epinephrine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Failure to obtain 6-7 hour pain score for 24/80 participants. Impact of large preponderance of slings placed by a subrapublic approach. Study not designed to examine the effect of phenazopyridine in study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Michael Flynn, MD</name_or_title>
      <organization>UMass Worcester</organization>
      <phone>508-334-9840</phone>
      <email>michael.flynn@umassmemorial.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

